This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HIV/AIDS	Not applicable	<i>In vitro</i> studies suggest antibody combinations derived from HIV patients with broadly neutralizing sera could help vaccinate against the virus. In sera from such patients, 17 mAbs showed cross-clade neutralization activity and had higher potency against viral strains than previously identified broadly neutralizing antibodies. Next steps include designing immunogens based on the antibodies to develop vaccines. Theraclone Sciences Inc. is studying the therapeutic potential of these broadly neutralizing antibodies in preclinical studies. SciBX 4(35); doi:10.1038/scibx.2011.991 Published online Sept. 8, 2011	Patents pending; HIV vaccines and their therapeutic applications available for licensing	Walker, L.M. <i>et al. Nature</i>; published online Aug. 17, 2011; doi:10.1038/nature10373 Contact: Dennis R. Burton, The Scripps Research Institute, La Jolla, Calif. e-mail: burton@scripps.edu